Genedrive (GB:GDR) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genedrive PLC, a leader in point-of-care pharmacogenetic testing, has announced a significant leadership change with the departure of CEO James Cheek and the appointment of former CSO Dr. Gino Miele PhD as his successor. Dr. Miele, who has been with the company since 2011, has played a crucial role in product development and regulatory approvals, contributing to the company’s strong position in the market. The company remains focused on expanding its product portfolio and market presence to drive growth.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.